Ameri Holdings

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

Enveric Biosciences went public last December. The company has two pre-clinical drug candidates using cannabinoids to treat cancer and its side-effects.

Enveric Biosciences Positioned To Test Cannabinoid-Based Cancer Treatments

NAPLES, FL / ACCESSWIRE / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will present at the Planet MicroCap Showcase to be held virtually on Wednesday, April 21, 2021 at 9:00 a.m. ET. To access the live presentation, please register here.

Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st

NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has appointed Carter Ward as Chief Financial Officer, effective May 15 th, 2021.

Enveric Biosciences Appoints Carter Ward as Chief Financial Officer

NAPLES, Fla., April 1, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid (CBD)_medicines to improve quality of life for cancer patients, today reported its financial results for the year ended December 31, 2020 and provided shareholders with an update on its accomplishments in 2021 thus far.

Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021

NEW YORK, March 18, 2021 /PRNewswire/ --  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the appointment of Dr. Douglas D. Lind to its board of directors.

Enveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors

LOS ANGELES, CA / ACCESSWIRE / March 17, 2021 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with David Johnson, Chairman, and CEO of Enveric Biosciences (NASDAQ:ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, according to the company's website (see here: www.enveric.com). Click the following link to watch the Video Interview: Enveric Biosciences on Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward You can follow SNN Network on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE Please review important disclosures on our website at http://stocknewsnow.com/legal.php#disclaimer About Enveric Biosciences Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients.

Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network

The stock price of Enveric Biosciences (NASDAQ: ENVB) has increased by over 10% pre-market. This is why it happened.

ENVB Stock Price Increases Over 10% Pre-Market: Why It Happened

ORLANDO, Fla., March 16, 2021 /PRNewswire/ -- Diverse Biotech, Inc. www.diversebiotech.com  announced today that it has finalized a strategic transaction with Enveric Biosciences to license exclusive worldwide development and commercialization rights for five novel compounds to address the adverse side effects of cancer treatments.

Diverse Biotech announces Strategic Transaction with Enveric Biosciences

NAPLES, Fla., March 15, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will participate in two upcoming investor conferences in March: M Vest and Maxim Group Inaugural Emerging Growth Conference to be held virtually on Thursday, March 18, 2021.

Enveric Biosciences to Participate in Upcoming Investor Conferences in March

Shares of Enveric Biosciences Inc. doubled in very heavy volume in midday trading Wednesday, after the Florida-based biotechnology company focused on cannabinoid-based treatments and cancer treatments said it acquired a perpetual license from Diverse Biotech for novel molecules for developing cancer treatments. Trading volume ballooned to 214.6 million shares, compared with the full-day average of about 2.4 million shares over the past 30 days.

CBD-focused Enveric Biosciences stock soars on heavy volume after license deal with cancer treatment company

Enveric (ENVB) stock has purchased the exclusive rights to research molecules that could lead to huge breakthroughs in CBD cancer treatment. The post ENVB Stock: Why Little-Known Enveric Biosciences is Soaring Today appeared first on InvestorPlace.

ENVB Stock: Why Little-Known Enveric Biosciences is Soaring Today

Enveric Biosciences Inc (NASDAQ: ENVB) soars in the premarket in reaction to acquiring an exclusive, perpetual license for novel molecules from Diverse Biotech. It is a biopharmaceutical company focused on developing new molecules for oncology.

Enveric Biosciences Stock Skyrockets After Licensing Agreement With Diverse Biotech

The stock price of Enveric Biosciences Inc (NASDAQ: ENVB) increased by over 80% pre-market. This is why it happened.

ENVB Stock Price Increased Over 80% Pre-Market: Why It Happened

NAPLES, Fla., March 10, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has acquired an exclusive, perpetual license from Diverse Biotech, a biopharmaceutical company focused on developing new molecules for treating oncology and other debilitating diseases.

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

NAPLES, Fla., Feb. 25, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has launched a strategic...

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs

NAPLES, Fla., Feb. 9, 2021 /PRNewswire/ -- Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into definitive...

Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Enveric Biosciences, Inc. (NASDAQ: ENVB), the...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Enveric Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NAPLES, Fla., Jan. 15, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing on January 14, 2021,...

Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering

AMERI Hlds

NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects...

News for Ameri Holdings Stock (ENVB)